Skip to main content
SpringerLink
Log in

Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes—proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS

  • Concise Review
  • Published:
Leukemia Submit manuscript

Abstract

Definite progress has been made in the exploration of myelodysplastic syndromes (MDS) by flow cytometry (FCM) since the publication of the World Health Organization 2008 classification of myeloid neoplasms. An international working party initiated within the European LeukemiaNet and extended to include members from Australia, Canada, Japan, Taiwan and the United States has, through several workshops, developed and subsequently published consensus recommendations. The latter deal with preanalytical precautions, and propose small and large panels, which allow evaluating immunophenotypic anomalies and calculating myelodysplasia scores. The current paper provides guidelines that strongly recommend the integration of FCM data with other diagnostic tools in the diagnostic work-up of MDS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1

Similar content being viewed by others

References

  1. Kern W, Haferlach C, Schnittger S, Haferlach T . Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome: correlation to cytomorphology, cytogenetics, and clinical data. Cancer 2010; 116: 4549–4563.

    Article  Google Scholar 

  2. van de Loosdrecht AA, Westers TM, Westra AH, Drager AM, van der Velden VH, Ossenkoppele GJ . Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. Blood 2008; 111: 1067–1077.

    Article  CAS  Google Scholar 

  3. Oka S, Muroi K, Fujiwara S, Oh I, Matsuyama T, Ohmine K et al. Prediction of progression from refractory cytopenia with unilineage dysplasia by analysis of bone marrow blast cell composition. J Clin Exp Hematop 2012; 52: 63–66.

    Article  Google Scholar 

  4. Della Porta MG, Lanza F, Del VL . Flow cytometry immunophenotyping for the evaluation of bone marrow dysplasia. Cytometry B Clin Cytom 2011; 80: 201–211.

    Article  Google Scholar 

  5. Chopra A, Pati H, Mahapatra M, Mishra P, Seth T, Kumar S et al. Flow cytometry in myelodysplastic syndrome: analysis of diagnostic utility using maturation pattern-based and quantitative approaches. Ann Hematol 2012; 91: 1351–1362.

    Article  Google Scholar 

  6. Chung JW, Park CJ, Cha CH, Cho YU, Jang S, Chi HS et al. A combination of CD15/CD10, CD64/CD33, CD16/CD13 or CD11b flow cytometric granulocyte panels is sensitive and specific for diagnosis of myelodysplastic syndrome. Ann Clin Lab Sci 2012; 42: 271–280.

    Google Scholar 

  7. Matarraz S, Lopez A, Barrena S, Fernandez C, Jensen E, Flores-Montero J et al. Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: a pilot study on a series of 56 patients. Cytometry B Clin Cytom 2010; 78: 154–168.

    Google Scholar 

  8. Truong F, Smith BR, Stachurski D, Cerny J, Medeiros LJ, Woda BA et al. The utility of flow cytometric immunophenotyping in cytopenic patients with a non-diagnostic bone marrow: a prospective study. Leuk Res 2009; 33: 1039–1046.

    Article  Google Scholar 

  9. Ogata K, Della Porta MG, Malcovati L, Picone C, Yokose N, Matsuda A et al. Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study. Haematologica 2009; 94: 1066–1074.

    Article  Google Scholar 

  10. Westers TM, Alhan C, Chamuleau ME, van der Vorst MJ, Eeltink C, Ossenkoppele GJ et al. Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment. Blood 2010; 115: 1779–1784.

    Article  CAS  Google Scholar 

  11. Westers TM, van der Velden VH, Alhan C, Bekkema R, Bijkerk A, Brooimans RA et al. Implementation of flow cytometry in the diagnostic work-up of myelodysplastic syndromes in a multicenter approach: report from the Dutch Working Party on Flow Cytometry in MDS. Leuk Res 2012; 36: 422–430.

    Article  Google Scholar 

  12. Falco P, Levis A, Stacchini A, Ciriello MM, Geuna M, Notari P et al. Prognostic relevance of cytometric quantitative assessment in patients with myelodysplastic syndromes. Eur J Haematol 2011; 87: 409–418.

    Article  CAS  Google Scholar 

  13. Chu SC, Wang TF, Li CC, Kao RH, Li DK, Su YC et al. Flow cytometric scoring system as a diagnostic and prognostic tool in myelodysplastic syndromes. Leuk Res 2011; 35: 868–873.

    Article  Google Scholar 

  14. Xu F, Guo J, Wu LY, He Q, Zhang Z, Chang CK et al. Diagnostic application and clinical significance of FCM progress scoring system based on immunophenotyping in CD34+ blasts in myelodysplastic syndromes. Cytometry B Clin Cytom 2013; 84: 267–278.

    Article  Google Scholar 

  15. Burbury KL, Westerman DA . Role of flow cytometry in myelodysplastic syndromes: diagnosis, classification, prognosis and response assessment. Leuk Lymphoma 2014; 55: 749–760.

    Article  CAS  Google Scholar 

  16. van Dongen JJ, Lhermitte L, Bottcher S, Almeida J, van der Velden VH, Flores-Montero J et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 2012; 26: 1908–1975.

    Article  CAS  Google Scholar 

  17. Arenillas L, Mallo M, Ramos F, Guinta K, Barragan E, Lumbreras E et al. Single nucleotide polymorphism array karyotyping: a diagnostic and prognostic tool in myelodysplastic syndromes with unsuccessful conventional cytogenetic testing. Genes Chromosomes Cancer 2013; 52: 1167–1177.

    Article  CAS  Google Scholar 

  18. Otrock ZK, Tiu RV, Maciejewski JP, Sekeres MA . The need for additional genetic markers for myelodysplastic syndrome stratification: what does the future hold for prognostication? Expert Rev Hematol 2013; 6: 59–68.

    Article  CAS  Google Scholar 

  19. Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014; 28: 241–247.

    Article  CAS  Google Scholar 

  20. Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van LP et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 2013; 122: 3616–3627.

    Article  CAS  Google Scholar 

  21. Bene MC . Immunophenotyping of myelodysplasia. Haematologica 2003; 88: 363.

    Google Scholar 

  22. Porwit A . Role of flow cytometry in diagnostics of myelodysplastic syndromes–beyond the WHO 2008 classification. Semin Diagn Pathol 2011; 28: 273–282.

    Article  Google Scholar 

  23. van de Loosdrecht AA, Westers TM . Cutting edge: flow cytometry in myelodysplastic syndromes. J Natl Compr Canc Netw 2013; 11: 892–902.

    Article  Google Scholar 

  24. Valent P, Horny HP, Bennett JM, Fonatsch C, Germing U, Greenberg P et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res 2007; 31: 727–736.

    Article  Google Scholar 

  25. Brunning R, Orazi A, Germing U, Le Beau M, Porwit A, Baumann I et al. Myelodysplastic syndromes/neoplasms, overview. In: Swerdlow S, Campo E, Harris NL, affe E, Pileri SA, Stein H, et al eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue.. Lyon: WHI, 2008; pp 88–93.

    Google Scholar 

  26. Malcovati L, Hellstrom-Lindberg E, Bowen D, Ades L, Cermak J, del CC et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 2013; 122: 2943–2964.

    Article  CAS  Google Scholar 

  27. van de Loosdrecht AA, Alhan C, Bene MC, Della Porta MG, Drager AM, Feuillard J et al. Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica 2009; 94: 1124–1134.

    Article  Google Scholar 

  28. Westers TM, Ireland R, Kern W, Alhan C, Balleisen JS, Bettelheim P et al. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia 2012; 26: 1730–1741.

    Article  CAS  Google Scholar 

  29. Greenberg PL, Attar E, Bennett JM, Bloomfield CD, De Castro CM, Deeg HJ et al. NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. J Natl Compr Canc Netw 2011; 9: 30–56.

    Article  Google Scholar 

  30. Greenberg PL, Attar E, Bennett JM, Bloomfield CD, Borate U, De Castro CM et al. Myelodysplastic syndromes: clinical practice guidelines in oncology. J Natl Compr Canc Netw 2013; 11: 838–874.

    Article  CAS  Google Scholar 

  31. Garcia-Manero G . Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol 2014; 89: 97–108.

    Article  CAS  Google Scholar 

  32. van de Loosdrecht AA, Ireland R, Kern W, Della Porta MG, Alhan C, Balleisen JS et al. Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group. Leuk Lymphoma 2013; 54: 472–475.

    Article  Google Scholar 

  33. Della Porta MG, Picone C, Pascutto C, Malcovati L, Tamura H, Handa H et al. Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study. Haematologica 2012; 97: 1209–1217.

    Article  Google Scholar 

  34. Wood B, Jevremovic D, Béné MC, Yan M, Jacobs P, Litwin V . ICSH/ICCS Working Group. Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS - part V - assay performance criteria. Cytometry B Clin Cytom 2013; 84: 315–323.

    Article  Google Scholar 

  35. Aalbers AM, van den Heuvel-Eibrink MM, de H V, Te Marvelde JG, de Jong AX, van der Burg M et al. Applicability of a reproducible flow cytometry scoring system in the diagnosis of refractory cytopenia of childhood. Leukemia 2013; 27: 1923–1925.

    Article  CAS  Google Scholar 

  36. Kussick SJ, Fromm JR, Rossini A, Li Y, Chang A, Norwood TH et al. Four-color flow cytometry shows strong concordance with bone marrow morphology and cytogenetics in the evaluation for myelodysplasia. Am J Clin Pathol 2005; 124: 170–181.

    Article  Google Scholar 

  37. Kern W, Bacher U, Schnittger S, Alpermann T, Haferlach C, Haferlach T . Multiparameter flow cytometry reveals myelodysplasia-related aberrant antigen expression in myelodysplastic/myeloproliferative neoplasms. Cytometry B Clin Cytom 2013; 84: 194–197.

    Article  Google Scholar 

  38. Della Porta MG, Alessandrino EP, Bacigalupo A, van Lint MT, Malcovati L, Pascutto C et al. Predictive factors for the outcome of allogeneic transplantation in patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System (IPSS-R). Blood 2014; 123: 2333–2342.

    Article  CAS  Google Scholar 

  39. Wells DA, Benesch M, Loken MR, Vallejo C, Myerson D, Leisenring WM et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood 2003; 102: 394–403.

    Article  CAS  Google Scholar 

  40. Xu F, Li X, Wu L, He Q, Zhang Z, Chang C . Flow cytometric scoring system (FCMSS) assisted diagnosis of myelodysplastic syndromes (MDS) and the biological significance of FCMSS-based immunophenotypes. Br J Haematol 2010; 149: 587–597.

    Article  Google Scholar 

  41. Ogata K, Kishikawa Y, Satoh C, Tamura H, Dan K, Hayashi A . Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes. Blood 2006; 108: 1037–1044.

    Article  CAS  Google Scholar 

  42. Stetler-Stevenson M, Arthur DC, Jabbour N, Xie XY, Molldrem J, Barrett AJ et al. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood 2001; 98: 979–987.

    Article  CAS  Google Scholar 

  43. Schanz J, Steidl C, Fonatsch C, Pfeilstocker M, Nosslinger T, Tuechler H et al. Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. J Clin Oncol 2011; 29: 1963–1970.

    Article  Google Scholar 

  44. Gupta R, Soupir CP, Johari V, Hasserjian RP . Myelodysplastic syndrome with isolated deletion of chromosome 20q: an indolent disease with minimal morphological dysplasia and frequent thrombocytopenic presentation. Br J Haematol 2007; 139: 265–268.

    Article  Google Scholar 

  45. Rashidi HH, Xu X, Wang HY, Shafi NQ, Rameshkumar K, Messer K et al. Utility of peripheral blood flow cytometry in differentiating low grade versus high grade myelodysplastic syndromes (MDS) and in the evaluation of cytopenias. Int J Clin Exp Pathol 2012; 5: 224–230.

    Google Scholar 

  46. Ogata K, Kakumoto K, Matsuda A, Tohyama K, Tamura H, Ueda Y et al. Differences in blast immunophenotypes among disease types in myelodysplastic syndromes: a multicenter validation study. Leuk Res 2012; 36: 1229–1236.

    Article  CAS  Google Scholar 

  47. Sandes AF, Kerbauy DM, Matarraz S, Chauffaille ML, Lopez A, Orfao A et al. Combined flow cytometric assessment of CD45, HLA-DR, CD34, and CD117 expression is a useful approach for reliable quantification of blast cells in myelodysplastic syndromes. Cytometry B Clin Cytom 2013; 84: 157–166.

    Article  Google Scholar 

  48. Matarraz S, Lopez A, Barrena S, Fernandez C, Jensen E, Flores J et al. The immunophenotype of different immature, myeloid and B-cell lineage-committed CD34+ hematopoietic cells allows discrimination between normal/reactive and myelodysplastic syndrome precursors. Leukemia 2008; 22: 1175–1183.

    Article  CAS  Google Scholar 

  49. De SD, Trullemans F, Jochmans K, Renmans W, Smet L, Heylen O et al. Diagnostic potential of CD34+ cell antigen expression in myelodysplastic syndromes. Am J Clin Pathol 2012; 138: 732–743.

    Article  Google Scholar 

  50. Monreal MB, Pardo ML, Pavlovsky MA, Fernandez I, Corrado CS, Giere I et al. Increased immature hematopoietic progenitor cells CD34+/CD38dim in myelodysplasia. Cytometry B Clin Cytom 2006; 70: 63–70.

    Article  Google Scholar 

  51. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120: 2454–2465.

    Article  CAS  Google Scholar 

  52. Sandes AF, Yamamoto M, Matarraz S, Chauffaille ML, Quijano S, Lopez A et al. Altered immunophenotypic features of peripheral blood platelets in myelodysplastic syndromes. Haematologica 2012; 97: 895–902.

    Article  Google Scholar 

  53. Xu F, Wu L, He Q, Zhang Z, Chang C, Li X . Immunophenotypic analysis of erythroid dysplasia and its diagnostic application in myelodysplastic syndromes. Intern Med J 2012; 42: 401–411.

    Article  CAS  Google Scholar 

  54. Mathis S, Chapuis N, Debord C, Rouquette A, Radford-Weiss I, Park S et al. Flow cytometric detection of dyserythropoiesis: a sensitive and powerful diagnostic tool for myelodysplastic syndromes. Leukemia 2013; 27: 1981–1987.

    Article  CAS  Google Scholar 

  55. Della Porta MG, Malcovati L, Invernizzi R, Travaglino E, Pascutto C, Maffioli M et al. Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome. Leukemia 2006; 20: 549–555.

    Article  CAS  Google Scholar 

  56. Krasselt M, Baerwald C, Wagner U, Rossol M . CD56+ monocytes have a dysregulated cytokine response to lipopolysaccharide and accumulate in rheumatoid arthritis and immunosenescence. Arthritis Res Ther 2013; 15: R139.

    Article  Google Scholar 

  57. Veltroni M, Sainati L, Zecca M, Fenu S, Tridello G, Testi AM et al. Advanced pediatric myelodysplastic syndromes: can immunophenotypic characterization of blast cells be a diagnostic and prognostic tool? Pediatr Blood Cancer 2009; 52: 357–363.

    Article  Google Scholar 

  58. Niemeyer CM, Baumann I . Classification of childhood aplastic anemia and myelodysplastic syndrome. Hematol Am Soc Hematol Educ Program 2011; 2011: 84–89.

    Article  Google Scholar 

  59. Hellstrom-Lindberg E, van de Loosdrecht A . Erythropoiesis stimulating agents and other growth factors in low-risk MDS. Best Pract Res Clin Haematol 2013; 26: 401–410.

    Article  CAS  Google Scholar 

  60. Alhan C, Westers TM, van der Helm LH, Eeltink C, Huls G, Witte BI et al. Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes. Cytometry B Clin Cytom 2014; 86: 207–215.

    Article  Google Scholar 

  61. Hrusak O, Porwit-MacDonald A . Antigen expression patterns reflecting genotype of acute leukemias. Leukemia 2002; 16: 1233–1258.

    Article  CAS  Google Scholar 

  62. Arnoulet C, Béné MC, Durrieu F, Feuillard J, Fossat C, Husson B et al. Four- and five-color flow cytometry analysis of leukocyte differentiation pathways in normal bone marrow: a reference document based on a systematic approach by the GTLLF and GEIL. Cytometry B Clin Cytom 2010; 78: 4–10.

    Google Scholar 

Download references

Author information

Author notes

  1. A Porwit, A A van de Loosdrecht, P Bettelheim, L Eidenschink Brodersen, K Burbury, E Cremers, M G Della Porta, R Ireland, U Johansson, S Matarraz, K Ogata, A Orfao, F Preijers, K Psarra, D Subirá, P Valent, V H J van der Velden, D Wells, T M Westers, W Kern and M C Béné: A Porwit, A A van de Loosdrecht, W Kern and M C Béné: These authors contributed equally to this work.

  2. Members of IMDSFlow are mentioned in Supplementary Appendix.

Authors and Affiliations

  1. Department of Pathobiology and Laboratory Medicine, University of Toronto, University Health Network, Toronto General Hospital, Toronto, Ontario, Canada

    A Porwit

  2. Department of Hematology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands

    A A van de Loosdrecht, E Cremers & T M Westers

  3. First Medical Department, Elisabethinen Hospital, Linz, Austria

    P Bettelheim

  4. HematoLogics, Inc., Seattle, WA, USA

    L Eidenschink Brodersen & D Wells

  5. Division of Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Melbourne, Victoria, Australia

    K Burbury

  6. Department of Hematology and Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, and University of Pavia, Pavia, Italy

    M G Della Porta

  7. King’s College Hospital, London, UK

    R Ireland

  8. University Hospitals, Bristol, UK

    U Johansson

  9. Instituto de Biologia Celular y Molecular del Cáncer CSIC/USAL/IBSAL) and Department of Medicine, Servicio Central de Citometría, Centro de Investigación del Cáncer, Universidad de Salamanca, Salamanca, Spain

    S Matarraz & A Orfao

  10. Metropolitan Research Center for Blood Disorders MRC JAPAN, Midorigaoka, Chofu, Tokyo, Japan

    K Ogata

  11. Department of Hematology, St Radboud University Medical Center, Nijmegen, The Netherlands

    F Preijers

  12. Department of Immunology-Histocompatibility, Evangelismos Hospital, Athens, Greece

    K Psarra

  13. Department of Hematology, Hospital Universitario de Guadalajara, Guadalajara, Spain

    D Subirá

  14. Department of Internal Medicine I, Division of Hematology and Hemostaseology and Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria

    P Valent

  15. Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands

    V H J van der Velden

  16. MLL Munich Leukemia Laboratory, Munich, Germany

    W Kern

  17. Service d'Hématologie Biologique, CHU de Nantes, Nantes, France

    M C Béné

Authors
  1. A Porwit
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A A van de Loosdrecht
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P Bettelheim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L Eidenschink Brodersen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K Burbury
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E Cremers
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M G Della Porta
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. R Ireland
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. U Johansson
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. S Matarraz
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. K Ogata
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. A Orfao
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. F Preijers
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. K Psarra
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. D Subirá
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. P Valent
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. V H J van der Velden
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. D Wells
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. T M Westers
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. W Kern
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. M C Béné
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of IMDSFlow

Corresponding author

Correspondence to M C Béné.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Porwit, A., van de Loosdrecht, A., Bettelheim, P. et al. Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes—proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS. Leukemia 28, 1793–1798 (2014). https://doi.org/10.1038/leu.2014.191

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2014.191

  • Springer Nature Limited

This article is cited by

Search

Navigation